 |
2003
OMIG, Abstract 16
OMIG
Main Page | 2003
Abstracts | <
Previous | Next>
The
Antimicrobial Preservative Efficacy of ZymarTM and VigamoxTM Against
Yeast Isolates
David Rupp, Teresa Reeves, Saroj Kapadia, Claude Anger
Microbiology Dept, Allergan, Inc.
Purpose:
To evaluate the antimicrobial preservative efficacy of ZymarTM (gatifloxacin
ophthalmic solution 0.3%) and VigamoxTM (moxifloxacin ophthalmic
solution 0.5%) against a variety of yeast isolates in vitro.
Methods: Candida albicans (4 strains), Candida
tropicalis (2), Candida parapsilosis (2), Cryptococcus neoformans
(2), Cryptococcus albidus (2), Candida guilliermondii (1), Candida
kefyr (1), Rhodotorula rubra (2), Yarrowia lipolytica (1) Geotrichum
candiun (1) and Torulopsios glabrata (2) were grown at 30-35oC
for 18-24 hours on Sabouraud dextrose agar. Test samples of commercially
available gatifloxacin and moxifloxacin were pooled and equal aliquots
of test sample were inoculated with each test organism to contain
approximately 1 x 105 to 1 x 106 colony forming
units (CFU) per mL of test solution. The samples were neutralized
and assayed at 4, 24, 48 hrs and 7 days to determine the number
of viable CFUs per mL of test solution.
Results: Overall moxifloxacin consistently allowed
more fungal recovery than gatifloxacin at every time point and for
every organism. For example, 11 of the moxifloxacin test strains
were shown to remain at levels of 105 CFU/mL at 24 hours while l7
of the gatifloxacin samples were reduced to levels of no recovery.
The cidal activity of gatifloxacin was shown to be very rapid. Eight
of the gatifloxacin test strains were reduced to levels of no recovery
at 4 hours, compared to 18 of the moxifloxacin test strains, which
remained at levels of 105 cells/mL. Seven-day moxifloxacin data
indicated that viable cells could still be recovered from 15 of
the test strains, whereas all 20 of the gatifloxacin samples demonstrated
no recovery.
Conclusions: ZymarTM, which is preserved with 0.005%
benzalkonium chloride (BAK), effectively kills a variety of potentially
pathogenic yeasts to a greater extent than does VigamoxTM, which
contains no BAK. This added benefit can reduce the potential introduction
of yeasts to the eye and surrounding structures during surgery and
during patient usage.
Financial support:
This study was supported by Allergan, Inc.
OMIG
Main Page | 2003
Abstracts | <
Previous | Next>
|
|
|
